NASDAQ$RGNX
REGENXBIO Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
REGENXBIO reported Q1 2026 revenue of $6.4M and continued gene therapy R&D investment.
For the three months ended March 31, 2026, REGENXBIO reported approximately $6.4 million of revenue, primarily collaboration and royalty-related, while funding AAV gene therapy programs. Net loss reflects elevated R&D on RGX-121, RGX-202, and partnered assets; see 10-Q for exact net loss and cash position.
- Revenue ~$6.4M from licenses and collaborations.
- Gene therapy platform focused on AAV therapeutics.
- R&D spend dominates operating expenses.
- Partnered programs with Novartis and others provide funding.
- Regulatory milestones for lead candidates drive sentiment.
Headline financials
Revenue & EPS history
REGENXBIO · Revenue · Quarterly
$6.39M
Forward guidance
Clinical-stage gene therapy company; guidance via milestone and trial timelines rather than product revenue.
Tailwinds
- Established AAV IP licensing revenue stream.
- Multiple clinical programs across therapeutic areas.
Headwinds
- Net losses until commercial launches.
- Clinical trial and FDA approval risks.
- Manufacturing scale-up requirements for AAV.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+0.8%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+1.7%
Avg return
30 days after
57%
24 / 42 earnings
Positive
+28.0%
Q4 2017
Best reaction
-37.8%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -37.8% | -43.8% | -33.8% | |
| Q4 2025 | -4.7% | +8.3% | -6.7% | |
| Q3 2025 | -3.6% | -0.5% | +13.4% | |
| Q1 2025 | +2.9% | +11.5% | +28.0% | |
| Q4 2024 | +2.6% | +29.8% | -10.1% | |
| Q3 2024 | +25.4% | +29.6% | +7.4% | |
| Q2 2024 | -8.5% | -10.9% | -14.2% | |
| Q1 2024 | -7.5% | -7.2% | -17.0% | |
| Q4 2023 | +8.5% | +15.5% | +14.9% | |
| Q3 2023 | +2.3% | +7.9% | +19.1% | |
| Q2 2023 | -8.7% | -8.4% | -5.3% | |
| Q1 2023 | +2.2% | -5.3% | +1.2% | |
| Q4 2022 | +10.0% | +11.2% | -17.6% | |
| Q3 2022 | -14.5% | -14.2% | +0.1% | |
| Q2 2022 | +9.2% | +9.4% | -6.9% | |
| Q1 2022 | -14.2% | -29.1% | -19.1% | |
| Q4 2021 | +11.1% | +5.3% | +26.6% | |
| Q3 2021 | +4.4% | +8.0% | -12.5% | |
| Q2 2021 | +0.1% | +0.4% | +6.9% | |
| Q1 2021 | +4.8% | +8.8% | +7.4% | |
| Q4 2020 | +1.0% | -2.4% | -16.6% | |
| Q3 2020 | +1.1% | +15.0% | +32.0% | |
| Q2 2020 | -3.4% | -2.5% | -16.9% | |
| Q1 2020 | -5.5% | -2.0% | -9.5% | |
| Q4 2019 | -14.8% | -15.8% | -28.7% | |
| Q3 2019 | -2.6% | +7.5% | +17.3% | |
| Q2 2019 | +0.6% | -8.5% | -22.5% | |
| Q1 2019 | -12.8% | -12.5% | -11.7% | |
| Q4 2018 | -2.2% | +7.0% | +8.3% | |
| Q3 2018 | -1.0% | -10.0% | -24.7% | |
| Q2 2018 | -5.8% | -6.6% | +4.4% | |
| Q1 2018 | +13.2% | +24.0% | +42.8% | |
| Q4 2017 | +28.0% | +22.9% | -3.4% | |
| Q3 2017 | +0.9% | +0.9% | +19.6% | |
| Q2 2017 | +11.8% | +12.4% | +33.3% | |
| Q1 2017 | -4.9% | +0.8% | +9.5% | |
| Q4 2016 | +6.6% | +2.5% | -10.2% | |
| Q3 2016 | +24.6% | +28.5% | +20.7% | |
| Q2 2016 | +0.8% | +21.3% | +41.5% | |
| Q1 2016 | -3.6% | — | — | |
| Q4 2015 | +1.8% | — | — | |
| Q3 2015 | +14.0% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro